Antenatal screening for aneuploidy

Current Opinion in Obstetrics and Gynecology

Volumn 10, Issue 2, 1998, Pages 91-96

  Chitty, Lyn S ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; ESTRIOL;

ANEUPLOIDY; DOWN SYNDROME; FETUS ECHOGRAPHY; FETUS HEART RATE; FIRST TRIMESTER PREGNANCY; HUMAN; KARYOTYPE; MATERNAL AGE; MATERNAL SERUM; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW; SCREENING; SECOND TRIMESTER PREGNANCY;

ALPHA-FETOPROTEINS; ANEUPLOIDY; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN; DOWN SYNDROME; FEMALE; GENETIC SCREENING; HUMANS; MATERNAL AGE; PREGNANCY; PREGNANCY, HIGH-RISK; PRENATAL DIAGNOSIS;

EID: 0031943588     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199804000-00003     Document Type: Review

References (65)

1. Van der Veen WJ, Beekhuis JR, Cornel MC, Mantingh A, De Walle HEK, De Wolf BTHM, A demographic approach to the assessment of Down syndrome screening performance. Prenat Diagn 1997; 17:717-724,
2. Wald NJ, Hackshaw AK, Huttly W, Kennard A. Empirical validation of risk screening for Down's syndrome. J Med Screening 1996; 3:185-187.
3. Huang T, Watt HC, Wald NJ. The effect of differences in the distribution of maternal age in England and Wales on the performance of prenatal screening for Down's syndrome. Prenat Diagn 1997; 17:615-621.
4. Cuckle HS, Holding S, Jones R, Groome NP, Wallace EM. Combining inhibin A with existing second-trimester markers in maternal serum screening for Down's syndrome. Prenat Diagn 1996; 16:1095-1100.
5. Spencer K, Wallace EM, Ritoe S. Second-trimester dimeric inhibin-A in Down's syndrome screening. Prenat Diagn 1996; 16:1101-1110.
6. Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG. Prenatal screening for Down's syndrome using inhibin-A as a serum marker. Prenat Diagn 1996; 16:143-153.
7. Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG, Watt H, et al. Inhibin-A in Down's syndrome pregnancies: revised estimate of standard deviation. Prenat Diagn 1997; 17:285-290.
8. Wald NJ, Watt HC, George L. Maternal serum inhibin-A in pregnancies with insulin-dependent diabetes mellitus: Implications for screening for Down's syndrome. Prenat Diagn 1996; 16:923-926.
9. Watt HC, Wald NJ, George L. Maternal serum inhibin-A levels in twin pregnancies: Implications for screening for Down's syndrome. Prenat Diagn 1996; 16:927-929.
10. Neveux LM, Palomaki GE, Knight GJ, Haddow JE. Multiple marker screening for Down syndrome in twin pregnancies. Prenat Diagn 1996; 16:29-34.
11. Ribbert LSM, Kornman LH, De Wolf BTHM, Simons AHM, Jansen CAM, Beekhuis JR, Mantingh A. Maternal serum screening for fetal Down syndrome in IVF pregnancies. Prenat Diagn 1996; 16:35-38.
12. Barkai G, Goldman B, Ries L, Chaki R, Dor J, Cuckle H. Down's syndrome screening marker levels following assisted reproduction. Prenat Diagn 1996; 16:1111-1114.
13. Spencer K. Between-pregnancy biological variability of maternal serum alpha-fetoprotein and free beta hCG: Implications for Down syndrome screening in subsequent pregnancies. Prenat Diagn 1997; 17:39-45.
14. Macri JN, Anderson RW, Krantz DA, Larsen JW, Buchannan PD. Prenatal maternal dried blood screening with β-human chorionic gonadotrophin for open neural tube defect and Down syndrome. Am J Obstet Gynecol 1996; 174:566-572.
15. Wald NJ, George L, Smith D, Densem JW, Petterson K. Serum screening • for Down's syndrome between 8 and 14 weeks of pregnancy. Br J Obstet Gynaecol 1996; 103:407-412. Useful review of biochemical markers in the first trimester of pregnancy.
16. Spencer K, Aitken DA, Macri JN, Buchanan PD. Urine free beta hCG and beta core in pregnancies affected by Down syndrome. Prenat Diagn 1996; 16:605-613.
17. Kellner LH, Canick JA, Palomaki GE, Saller DN, Lambert-Meserlian GM, Neuer M, et al. Urinary markers: a new approach to screening for Down syndrome in the second trimester. Am J Hum Genet 1996; 59:A41(207).
18. Isozaki T, Palomaki GE, Bahado-Singh RO, Cole LA. Screening for Down syndrome pregnancy using β-core fragment: prospective study. Prenat Diagn 1997; 17:407-413.
19. Macintosh MCM, Nicolaides KH, Noble P, Chard T, Gunn L, Lles R. Urinary β-core hCG: Screening for aneuploidies in early pregnancy (11-14 weeks' gestation). Prenat Diagn 1997; 17:401-405.
20. Snijders RJM, Johnson S, Sebire NJ, Noble PL, Nicolaides KH. First- • trimester ultrasound screening for chromosomal defects. Ultrasound Obstet Gynecol 1996; 7:216-226. Review article describing methods of aneuploidy screening in first trimester.
21. Chitty LS, Pandya PP. Ultrasound screening for fetal abnormalities in the • first trimester. Prenat Diagn 1997; 17, in press. Includes a comprehensive review of the literature on the usefulness of nuchal translucency measurement in screening for aneuploidy.
22. Scott F, Boogert A, Sinosich M, Anderson J. Establishment and application of a normal range for nuchal translucency across the first trimester. Prenat Diagn 1996; 16:629-634.
23. Sebire NJ, Snijders RJM, Hughes K, Sepuldeva W, Nicolaides KN. Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Br J Obstet Gynaecol 1996; 103:999-1003.
24. Hyett JA, Sebire NJ, Snijders RJM, Nicolaides KH. Intrauterine lethality of trisomy 21 fetuses with increased nuchal translucency thickness. Ultrasound Obstet Gynecol 1996; 7:101-103.
25. Kornan LP, Morssink JR, de Wolf BTHM, Heringa MP, Mantingi A. Nuchal translucency cannot be used as a screening test for chromosomal abnormalities in the first trimester of pregnancy in a routine ultrasound practice. Prenat Diagn 1996; 16:797-805.
26. Haddow JE, Palomaki GE. Down's syndrome screening. Lancet 1996; 347:1625.
27. Thilaganathan B, Slack A, Wathen NC. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome. Ultrasound Obstet Gynecol 1997; 10:261-264.
28. Braithwaite JM, Kadir RA, Pepea TA, Morris RW, Thompson PJ, Economides DL. Nuchal translucency measurement: training of potential examiners. Ultrasound Obstet Gynecol 1996; 8:192-195.
29. Biagiotti R, Periti E, Brizzi L, Vanzi E, Cariati E. Comparison between two methods of standardisation for gestational age differences in fetal nuchal translucency measurement in first-trimester screening for trisomy 21. Ultrasound Obstet Gynecol 1997; 9:248-252.
30. Hyett J, Noble PL, Snijders RJM, Montenegro N, Nicolaides KH. Fetal heart rate in trisomy 21 and other chromosomal abnormalities at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 1996; 7:239-244.
31. Jauniaux E, Gavrill P, Khun P, Kurdi W, Hyett J, Nicolaides KH. Fetal heart rate and umbilico-placental Doppler flow velocity waveforms in early pregnancies with a chromosomal abnormality and/or increased nuchal translucency thickness. Hum Reprod 1996; 11:435-439.
32. Martinez JM, Comas C, Ojuel J, Borrell A, Puerto B, Fortuny A. Fetal heart rate patterns in pregnancies with chromosomal disorders or subsequent fetal loss. Obstet Gynecol 1996; 87:118-121.
33. Schemmer G, Wapner RJ, Johnson A, Schemmer M, Norton HJ, Anderson WE. First-trimester growth patterns of aneuploid fetuses. Prenat Diagn 1997; 17:155-159.
34. Guarigla L, Rosati P. Fetal biometric ratios by transvaginal sonography as a marker for aneuploidies in early pregnancy. Prenat Diagn 1997; 17:415-422.
35. Bahado-Singh RO, Lynch L, Deren O, Morroti R, Copel JA. Mahoney MJ, Williams J III. First-trimester growth restriction and fetal aneuploidy: The effect of type of aneuploidy and gestational age. Am J Obstet Gynecol 1997; 176:976-979.
36. Sebire NJ, Kaisenberg von C, Rubio C, Snijders RJM, Nicolaides KH. Fetal megacystis at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 1996; 8:367-390.
37. Scott F, Wheeler D, Sinosich M, Boogert A, Anderson J, Edelman D. First trimester aneuploidy screening using nuchal translucency, free beta human chorionic gonadotrophin and maternal age. Aust NZ J Obstet Gynaecol 1996; 36:381.
38. Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn 1997; 17:821-629.
39. Spencer K, Noble P, Snijders RJM, Nicolaides KH. First-trimester urine free beta hCG, beta core, and total oestriol in pregnancies affected by Down's syndrome: Implications for first-trimester screening with nuchal translucency and serum free beta hCG. Prenat Diagn 1997; 17:525-538.
40. Benacerraf BR. The second-trimester fetus with Down syndrome: • detection using sonographic features. Ultrasound Obstet Gynecol 1996; 7:147-155. Useful review of sonographic markers of Downs syndrome.
41. Hill LM. The sonographic detection of trisomies 13, 18 and 21. Clin Obstet Gynecol 1996; 39:831-850. Useful review of ultrasound markers of major trisomies.
42. Bernaschek G, Kolankaya A, Stuempfen I, Deutinger MT, Deutinger J. Chromosomal abnormalities: how much can we predict by ultrasound examination in low-risk pregnancies? Am J Perinatol 1996; 13:259-263.
43. Rotmensch S, Liberati M, Bronshtein M, Schoenfeld-Dimaio M, Shalev J, Ben-Rafel Z, Copel JA. Prenatal sonographic findings in 187 fetuses with Down syndrome. Prenat Diagn 17:1001-1009.
44. Vintzileos AM, Campbell WA, Guzman ER, Smullian JC, McLean DA, Ananth CV. Second-trimester ultrasound markers for detection of trisomy 21: which markers are best? Obstet Gynecol 1997: 89:941-944.
45. Vintzileos AM, Campbell WA, Rodis JF, Guzman ER, Smulian JC, Knuppel RA. The use of second-trimester genetic sonogram in guiding clinical management of patients at increased risk for fetal trisomy 21. Obstet Gynecol 1996; 87:948-952.
46. Snijders RJ. Isolated choroid plexus cysts: should we offer karyotyping? Ultrasound Obstet Gynecol 1996; 8:223-224.
47. Gray DL, Winborn RC, Suessen TL, Crane JP. Is genetic amniocentesis warranted when isolated choroid plexus cysts are found? Prenat Diagn 1996; 16:983-990.
48. Kilby M, Whittle M, North L, McHugo J. Isolated choroid plexus cysts and aneuploidy. Prenat Diagn 1997; 17:785-790.
49. Sharony R. Fetal choroid plexus cysts - is a genetic evaluation indicated? Prenat Diagn 1997; 17:519-524.
50. Gratton RJ, Hogge WA, Aston CE. Choroid plexus cysts and trisomy 18: risk modification based on maternal age and multiple-marker screening. Am J Obstet Gynecol 1996; 175:1493-1497.
51. Remsch RC. Choroid plexus cysts - association with trisomy. Prospective review of 16,059 patients. Am J Obstet Gynecol 1997; 176:1381-1383.
52. Donnenfeld AE. Risk and benefit analysis of offering karyotyping for an isolated choroid plexus cyst. Ultrasound Obstet Gynecol 1997; 9:67-68.
53. Bronshtein M, Jakobi P, Ofir C. Multiple fetal intracardiac echogenic foci: not always a benign sonographic finding. Prenat Diagn 1996; 16:131-135.
54. Simpson JM, Cook A, Sharland G. The significance of echogenic foci in the fetal heart: a prospective study of 228 cases. Ultrasound Obstet Gynecol 1996; 8:225-228.
55. Achiron R, Lipitz S, Gabbay U, Yagel S. Prenatal ultrasonographic • diagnosis of fetal heart echogenic foci: no correlation with Down syndrome. Obstet Gynecol 1997; 89:945-948. Good study and review.
56. Petrikovsky BM, Schneider EP, Klein VR, Wyse LJ, Lesser M. Fetal breasts in normal and Down syndrome fetuses. J Clin Ultrasound 1996; 24:507-511.
57. Shimizu T, Salvador L, Hughes-Benzie R, Dawson L, Nimrod C, Allanson J. The role of reduced ear size in the prenatal detection of chromosomal abnormalities. Prenat Diagn 1997; 17:545-549.
58. Bork MD, Egan JFX, Cusick W, Borgida AF, Campbell WA, Rodis JF. Iliac wing angle as a marker for trisomy 21 in the second trimester. Obstet Gynecol 1997; 89:734-737.
59. Kliewer MK, Hertzberg BS, Freed KS, DeLong D, Kay HH, Jordan SG. et al. Dysmorphologic features of the fetal pelvis in Down syndrome: prenatal sonographic depiction and diagnostic implications of the iliac angle. Radiology 1996; 201:681-684.
60. Drugan A, Johnson MP, Reichler A, Hume R, Itskovicz-Eldor J, Evans MI. Second-trimester minor ultrasound anomalies: Impact on the risk of aneuploidy associated with advanced maternal age. Obstet Gynecol 1996; 88:203-206.
61. Palomaki GE, Neveux LM, Haddow JE. Can reliable Down's syndrome • detection rates be determined from prenatal screening intervention trials? J Med Screening 1996; 3:12-17. Useful comment on how to compare screening studies.
62. Mackintosh MCM, Wald NJ, Chad T, Hansen J, Mikkelsen M, Therkelsel AJ, et al. The selective miscarriage of Down's syndrome from 10 weeks of pregnancy. Br J Obstet Gynaecol 1996; 103:1171-1172.
63. Nicolaides KH, Sebire NJ, Snijders RJM. Down's syndrome screening with nuchal translucency. Lancet 1997; 349:438.
64. Hahnemann JM, Verjerslev LO. Accuracy of cytogenetic findings on chononic villus sampling (CVS) - diagnostic consequences of CVS mosaicism and non-mosaic discrepancy in centres contributing to eucromic 1986-1992. Prenat Diagn 1997; 17:801-820.
65. Kadir RA, Economides DL. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome. Ultrasound Obstet Gynecol 1997; 9:244-247.